Tandem Diabetes Care, Inc. (TNDM)
| Market Cap | 1.15B +22.6% |
| Revenue (ttm) | 1.04B +4.0% |
| Net Income | -63.32M |
| EPS | -0.93 |
| Shares Out | 69.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,590,447 |
| Open | 16.01 |
| Previous Close | 16.01 |
| Day's Range | 15.61 - 16.55 |
| 52-Week Range | 12.26 - 29.65 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 27.76 (+68.04%) |
| Earnings Date | Nov 5, 2026 |
About TNDM
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a pe... [Read more]
Financial Performance
In 2025, Tandem Diabetes Care's revenue was $1.01 billion, an increase of 7.93% compared to the previous year's $940.20 million. Losses were -$204.71 million, 113.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for TNDM stock is "Buy." The 12-month stock price target is $27.76, which is an increase of 68.04% from the latest price.
News
Tandem Diabetes price target lowered to $18 from $20 at Mizuho
Mizuho analyst Anthony Petrone lowered the firm’s price target on Tandem Diabetes (TNDM) to $18 from $20 and keeps a Neutral rating on the shares. The firm adjusted targets in…
Tandem Diabetes initiated with an Equal Weight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Tandem Diabetes (TNDM) with an Equal Weight rating and $18 price target The firm rolled out coverage of the medical suppliers and devices…
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial m...
Citi cuts Tandem target, opens ‘upside 90-day catalyst watch’
Citi analyst Joanne Wuensch lowered the firm’s price target on Tandem Diabetes (TNDM) to $20 from $24 and keeps a Neutral rating on the shares. Citi also opened an “upside…
Tandem Diabetes says Tandem Mobi now available in 12 international markets
Tandem Diabetes (TNDM) Care announced that Tandem Mobi, the world’s smallest, durable automated insulin delivery system for people living with diabetes, is now available in 12 countries outside the Un...
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Diabetes initiated with an Outperform at William Blair
William Blair initiated coverage of Tandem Diabetes (TNDM) with an Outperform rating. The firm believes the company is positioned to be the next player to enter the tubeless pump market.
Tandem Diabetes price target raised to $24 from $21 at Citi
Citi analyst Joanne Wuensch raised the firm’s price target on Tandem Diabetes (TNDM) to $24 from $21 and keeps a Neutral rating on the shares. The firm is more optimistic…
Tandem Diabetes Care Transcript: Canaccord Genuity's 46th Annual Growth Conference
Diabetes pump therapy remains under-penetrated, and the company is driving growth through product innovation, a new pay-as-you-go pharmacy model, and international direct sales expansion. Key upcoming milestones include the launch of a tubeless pump and a fully closed loop system, with a focus on affordability, clinical outcomes, and operational efficiency.
Tandem Diabetes price target lowered to $26 from $30 at RBC Capital
RBC Capital analyst Kendall Au lowered the firm’s price target on Tandem Diabetes (TNDM) to $26 from $30 and keeps an Outperform rating on the shares. Tandem delivered an in-line…
Tandem Diabetes price target raised to $40 from $35 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on Tandem Diabetes (TNDM) to $40 from $35 and keeps a Buy rating on the shares. The firm said Tandem delivered…
Tandem Diabetes price target raised to $21 from $17 at Citi
Citi raised the firm’s price target on Tandem Diabetes (TNDM) to $21 from $17 and keeps a Neutral rating on the shares.
Tandem Diabetes Care Earnings Call Transcript: Q2 2026
Record Q2 with 10%+ pump shipment growth, 6% sales increase, and 57% gross margin. Pharmacy PayGo adoption reached 10% of U.S. sales, and Mobi Tubeless FDA submission sets up a major H2 launch. Guidance reaffirmed with highest margins expected in Q4.
Tandem Diabetes Care Slides: Q2 2026
Tandem Diabetes Care has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Tandem Diabetes Care Earnings release: Q2 2026
Tandem Diabetes Care released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tandem Diabetes Care Quarterly report: Q2 2026
Tandem Diabetes Care has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) (the Company), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter end...
Tandem Diabetes Care Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at Cana...
Tandem Diabetes resumed with a Neutral at UBS
UBS resumed coverage of Tandem Diabetes (TNDM) with a Neutral rating with a price target of $18, down from $22, as part of a broader note on U.S. Medical Supplies…
Tandem Diabetes price target lowered to $20 from $24 at Mizuho
Mizuho lowered the firm’s price target on Tandem Diabetes (TNDM) to $20 from $24 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical device…
Tandem Diabetes launches t:slim X2 compatibility with Abbott’s FreeStyle
Tandem Diabetes Care (TNDM) announced that the t:slim X2 insulin pump with Control-IQ+ automated insulin delivery, AID, technology is now compatible with Abbott’s (ABT) FreeStyle Libre 3 Plus continuo...
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
SAN DIEGO--(BUSINESS WIRE)---- $TNDM #diabetes--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott's FreeStyle Libre 3 Plus CGM sensor in five EU countries.
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial ...
Tandem Diabetes initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Kieran Ryan initiated coverage of Tandem Diabetes (TNDM) with a Hold rating and $15.50 price target The ongoing transition to pay-go pharmacy is a “transformational shift” to…
Tandem Diabetes Care Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The conference highlighted strong momentum in product innovation, including the CE Mark for pregnancy indication and the upcoming Mobi Tubeless launch. The pharmacy channel transition is progressing, aiming to reduce out-of-pocket costs and drive growth, while international expansion and new technology initiatives are set to further strengthen market position.